EGFR and non-small cell lung carcinoma: What’s more, our previous laboratory study has revealed that SFI combined with gefitinib can inhibit the proliferation and cloning of NSCLC resistant cells, and potentiate the binding of gefitinib to EGFR target depending on the suppression of MAPK/SREBP1 pathway (Pan et al. 2020).